Table 1.

Patient characteristics in training set and testing set

		Train	Test	P-value
Treatment	Paclitaxel	95	47	0.448
	Paclitaxel + ABT 888 + Carboplatin	40	17
	Paclitaxel + AMG 386	73	23
	Paclitaxel + AMG 386 + Trastuzumab	12	4
	Paclitaxel + Ganetespib	59	19
	Paclitaxel + Ganitumab	69	20
	Paclitaxel + MK-2206	32	14
	Paclitaxel + MK-2206 + Trastuzumab	25	5
	Paclitaxel + Neratinib	70	15
	Paclitaxel + Pembrolizumab	44	10
	Paclitaxel + Pertuzumab + Trastuzumab	23	10
	Paclitaxel + Trastuzumab	16	4
	T-DM1 + Pertuzumab	30	9
HR	negative	265	89	1
	positive	323	108
HER2	negative	454	157	0.322
	positive	144	40
MP	negative	304	102	1
	positive	284	95
pCR	negative	398	133	1
	positive	190	64
Age (mean, range)		49 (25–77)	50 (23–72)	0.238
Race	American Indian or Alaska Native	4	0	0.434
	American Indian or Alaska Native; White	0	1
	Asian	43	14
	Asian; White	3	1
	Black or African American	71	22
	Native Hawaiian or Pacific Islander	4	0
	Native Hawaiian or Pacific Islander; White	0	1
	White	461	157
	N/A	2	1
Menopausal status	N/A	103	43	0.362
	Perimenopausal	21	7
	Postmenopausal	177	64
	Premenopausal	287	83
Ethnicity	Hispanic or Latino	76	28	0.723
	Not Hispanic or Latino	511	169
	N/A	1	0